⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31756381 | 0.85 | — | — | |
| SCHEMBL19743779 | 0.81 | — | — | |
| SCHEMBL13086010 | 0.77 | — | — | |
| SCHEMBL2067650 | 0.76 | — | — | |
| SCHEMBL2875605 | 0.75 | — | — | |
| SCHEMBL29407772 | 0.75 | — | — | |
| SCHEMBL19490794 | 0.75 | — | — | |
| SCHEMBL151857 | 0.75 | — | — | |
| SCHEMBL31057600 | 0.73 | AXL (0.42) | — | |
| SCHEMBL16213734 | 0.73 | AXL (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107177587-A | Modification ceramic tile particulate vector for fixing thimet degradation bacteria and preparation method thereof | 光合强化（北京）生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| CN-106975460-A | Modified corn core adsorbent for Adsorption kanamycins | 北京益净环保设备科技有限公司 | 2017-07-25 | — | — | CN | claimed |
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-12528786-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-1930145-B | Cycloalkanopyridine derivative | MSD CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1930145-A | Cycloalkanopyridine derivative | BANYU PHARMA CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |